Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada
- Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, recently received conditional marketing authorisation in Europe from the European Commission - Exclusive licensing and supply agreements have been granted to Medexus for the Canadian commercialization rights for Zemcelpro® (if...
- Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, recently received conditional marketing authorisation in Europe from the European Commission - Exclusive licensing and supply agreements have been granted to Medexus for the Canadian commercialization rights for Zemcelpro® (if...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.